| Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD) (NCT03855865) | Naurex, Inc, an affiliate of Allergan plc | 2019-07-01 |
| Assessment of Effect of Rapastinel on Driving Performance (NCT03814733) | Naurex, Inc, an affiliate of Allergan plc | 2018-11-05 |
| Assessment of Abuse Potential of Rapastinel in Humans (NCT03799900) | Naurex, Inc, an affiliate of Allergan plc | 2018-11-01 |
| Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD) (NCT03675776) | Naurex, Inc, an affiliate of Allergan plc | 2018-10-30 |
| Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) (NCT03668600) | Naurex, Inc, an affiliate of Allergan plc | 2018-08-23 |
| Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD) (NCT03614156) | Naurex, Inc, an affiliate of Allergan plc | 2018-08-02 |
| Study of Rapastinel as Monotherapy in Patients With MDD (NCT03560518) | Naurex, Inc, an affiliate of Allergan plc | 2018-06-15 |
| A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder (NCT03352453) | Naurex, Inc, an affiliate of Allergan plc | 2017-12-15 |
| Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder (NCT03002077) | Naurex, Inc, an affiliate of Allergan plc | 2017-02-03 |
| A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder (NCT02951988) | Naurex, Inc, an affiliate of Allergan plc | 2016-11-13 |
| A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03) (NCT02943577) | Naurex, Inc, an affiliate of Allergan plc | 2016-11-02 |
| A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02) (NCT02943564) | Naurex, Inc, an affiliate of Allergan plc | 2016-11-01 |
| A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01) (NCT02932943) | Naurex, Inc, an affiliate of Allergan plc | 2016-10-15 |
| Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers (NCT02366364) | Naurex, Inc, an affiliate of Allergan plc | 2015-02-01 |
| Open Label Extension for GLYX13-C-202, NCT01684163 (NCT02192099) | Naurex, Inc, an affiliate of Allergan plc | 2014-09-08 |
| Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder (NCT02067793) | Naurex, Inc, an affiliate of Allergan plc | 2014-03-01 |
| Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers (NCT01856556) | Naurex, Inc, an affiliate of Allergan plc | 2013-05-01 |
| Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants (NCT01684163) | Naurex, Inc, an affiliate of Allergan plc | 2012-11-01 |
| Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression (NCT01234558) | Naurex, Inc, an affiliate of Allergan plc | 2011-05-01 |
| Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers (NCT01014650) | Naurex, Inc, an affiliate of Allergan plc | 2009-11-01 |